Michael Okunewitch
Stock Analyst at Maxim Group
(1.23)
# 3,728
Out of 5,114 analysts
30
Total ratings
26.92%
Success rate
-9.34%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNRX VolitionRx | Downgrades: Hold | n/a | $0.26 | - | 1 | Dec 3, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $5 → $10 | $1.51 | +562.25% | 1 | Oct 20, 2025 | |
| CTOR Citius Oncology | Upgrades: Buy | $6 | $1.39 | +331.65% | 3 | Sep 23, 2025 | |
| ANEB Anebulo Pharmaceuticals | Downgrades: Hold | n/a | $2.17 | - | 3 | Jul 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $1.57 | +2,129.30% | 2 | May 29, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $5.19 | +131.21% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $16 → $28 | $1.89 | +1,381.48% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $1.20 | +1,066.67% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.68 | +78.57% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.40 | +185.71% | 1 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.26 | +4,542.17% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $6 | $0.56 | +975.27% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.58 | +1,959.73% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $2.16 | +1,011.11% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.16 | +733.33% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $2.11 | +95,871.56% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $18.77 | +33.19% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.15 | +421.74% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.96 | +531.31% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.07 | +9,245.79% | 1 | Nov 30, 2021 |
VolitionRx
Dec 3, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.26
Upside: -
Rani Therapeutics Holdings
Oct 20, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $1.51
Upside: +562.25%
Citius Oncology
Sep 23, 2025
Upgrades: Buy
Price Target: $6
Current: $1.39
Upside: +331.65%
Anebulo Pharmaceuticals
Jul 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.17
Upside: -
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $1.57
Upside: +2,129.30%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $5.19
Upside: +131.21%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $16 → $28
Current: $1.89
Upside: +1,381.48%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $1.20
Upside: +1,066.67%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.68
Upside: +78.57%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.40
Upside: +185.71%
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.26
Upside: +4,542.17%
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.56
Upside: +975.27%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.58
Upside: +1,959.73%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $2.16
Upside: +1,011.11%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.16
Upside: +733.33%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $2.11
Upside: +95,871.56%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $18.77
Upside: +33.19%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.15
Upside: +421.74%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $3.96
Upside: +531.31%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $1.07
Upside: +9,245.79%